匹诺塞林合成生物学研究进展.pdfVIP

生 物 工 程 学 报 郭磊 等/ 匹诺塞林合成生物学研究进展 451 Chinese Journal of Biotechnology /cjbcn April 25, 2015, 31(4): 451−460 DOI: 10.13345/j.cjb.140367 ©2015 Chin J Biotech, All rights reserved 综 述 郭磊，孔建强 100050 , . . , 2015, 31(4): 451–460. Guo L, Kong JQ. Progress in synthetic biology of pinocembrin. Chin J Biotech, 2015, 31(4): 451–460. 摘 要: 匹诺塞林是一种广泛存在于植物中的黄酮类化合物，具有很好的生物活性，如神经保护、抗菌、抗 氧化等。2009 年，匹诺塞林被 CFDA 批准为 Ⅰ类注射新药，主要用于治疗急性脑卒中，现已经进入Ⅱ期临床 试验阶段。匹诺塞林的良好成药性使其合成方法备受关注。匹诺塞林可以通过化学合成、植物提取和合成生物 学技术制备。合成生物学技术是一种环境友好的工程化生物技术，代表未来匹诺塞林的合成发展方向。文中总 结了利用合成生物学技术制备匹诺塞林的研究现状，并从选择酶的物种来源、提高丙二酰 CoA 含量、选择经 济的底物及减弱中间产物的抑制作用等角度系统地总结了提高微生物合成匹诺塞林的策略。 : 匹诺塞林，黄酮类化合物，合成生物学，发酵策略 Progress in synthetic biology of pinocembrin Lei Guo, and Jianqiang Kong Key Laboratory of Biosynthesis of Natural Products, Ministry of Health of PRC, State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Material Medica, Chinese Academy of Medical Sciences Peking Union Medical College, Beijing 100050, China Abstract: Pinocembrin, belonging to flavanons, was isolated from various plants. Pinocembrin has a variety of pharmacological activities, such as neuroprotective effect, antimicrobial activity, and antioxidant efficacy. Pinocembrin was approved as class Ⅰdrugs to its phase Ⅱ clinical trial by CFDA in 2009, mainly used for the treatment of ischemic stroke. As a promising compound, the manufacturing technologies of pinocembrin, including chemical synthesis, extraction from plant and synthetic biology, have attracted many attentions. Compared with the first two technologies, synthetic Received: July 14, 2014; A